Astrazeneca ADR Stock
Your prediction
Astrazeneca ADR Stock
Astrazeneca ADR gained 1.410% today.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Astrazeneca ADR stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Astrazeneca ADR in the next few years
Pros
?
B****
?
M***** P*******
?
S********** s********
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Astrazeneca ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Astrazeneca ADR | 1.410% | -0.690% | 0.699% | 5.109% | 17.073% | 54.506% | - |
| GSK plc ADR | 1.470% | -0.481% | 8.377% | 31.013% | 23.214% | 3.500% | -4.277% |
| Bayer AG ADR | -6.430% | -2.963% | -0.758% | -50.000% | -23.837% | -50.000% | -50.000% |
| Roche Holding AG ADR | 1.620% | 1.262% | 5.554% | -20.397% | -8.789% | -17.553% | - |
News
This Pharma Stock Is Poised to Keep Outperforming the S&P 500
AstraZeneca (NASDAQ: AZN), recognized as the world's sixth-largest pharmaceutical entity by market capitalization, made a bold proclamation in May 2014. The company set an ambitious goal of
AstraZeneca Plans to Rake in $80 Billion by 2030. Should You Buy the Stock?
AstraZeneca (NASDAQ: AZN) is embarking on a fresh business plan that will see it grow significantly between now and 2030. If it succeeds, it'll be a company that's even more prominent in the global
Forget Johnson & Johnson: Buy This Better Healthcare Stock Instead
Many healthcare investors look at Johnson & Johnson (NYSE: JNJ) and see a good, safe dividend stock. But I see an investment that's full of uncertainty and risk.
The company continually runs into